

Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Ref: FOI-062023-000137

Date: 6/7/23

Address / Email:

## **Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000, please see your response below.

## Request

Q1 - How many patients has your Trust treated in the past 3 months for:

- · Non-small cell lung cancer (NSCLC) any treatment
- · Non-small cell lung cancer (NSCLC) surgical treatment
- · Non-small cell lung cancer (NSCLC) radiotherapy
- Non-small cell lung cancer (NSCLC) systemic anti-cancer treatment (SACT)

| Diagnosis  | Treatment Type | No. of<br>Patients |
|--|----------------|--------------------|
| Non-small cell lung cancer (NSCLC)   | any treatment  | 46                 |
| Non-small cell lung cancer (NSCLC)   | Surgery        | 8                  |
| Non-small cell lung cancer (NSCLC)   | Radiotherapy   | 8                  |
| Non-small cell lung cancer (NSCLC) - systemic anti-<br>cancer treatment (SACT) |                | 53                 |

Q2 - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 5
- · Amivantamab
- Atezolizumab monotherapy 1
- Atezolizumab with chemotherapy 0
- Dabrafenib + Trametinib
- Durvalumab
- Gemcitabine 1
- · Nitendanib + Docetaxel 1
- Nivolumab
- · Osimertinib 9
- · Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 3
- Paclitaxel

## FOI/REF FOI-

- Pembrolizumab monotherapy 19
- Pembrolizumab with chemotherapy 5
- Pemetrexed with carboplatin/cisplatin 7
- RET Inhibitors (Pralsetinib, Selpercatinib)
- · Sotorasib
- · Tepotinib
- · Vinorelbine monotherapy or combination with Carboplatin/Cisplatin 2
- Other active systemic anti-cancer therapy [please state] Docetaxel Monotherapy 2, E-Carboplatin 1, Pemetrexed Monotherapy 1
- Palliative care only

Q3 - Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab? – N/A

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ Email: <u>dgft.dpo@nhs.net</u>

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team The Dudley Group NHS Foundation Trust